Biopharma companies are increasingly turning to developing nations as sites for clinical trials, driven by a ready supply of patients, the ability to tackle diseases that are rare in industrialized nations, and large potential markets. "Competition for available patients in industrialized nations is a major challenge in new product development," notes Joe Shan, executive director of clinical and regulatory affairs at Peregrine Pharmaceuticals (www.peregrineinc.com). Developing nations, however, offer less competition from other clinical trials and plenty of patients and investigators who are eager to participate.
展开▼
